4 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
To evaluate the efficacy of crovalimab compared to eculizumab
Approved WMOCompleted
This study has multiple purposes:Primary objective:1: to investigate whether it is possible to identify the small mimic muscles independently of each other and to determine the exact position of the origin and insertion of the mimic muscles on 7…
Approved WMOPending
To evaluate the safety and tolerability of crovalimab compared witheculizumab